Primary outcomes: reduction in CVDs and major cardiovascular events (MACEs). Secondary outcomes: examining novel biomarkers (IL-6, IL-1β), pericarditis resolution/CVDs occurrence, and complications. Here, IL1B is linked to pericarditis.